Zhifei BioinfluenzaThe vaccine matrix has added another blockbuster product. The company announced on the evening of September 29 that the influenza virus split vaccine (referred to as "trivalent influenza vaccine"; registration category: preventive biological product) recently developed by its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.) Obtain the "Drug Registration Certificate" issued by the State Food and Drug Administration.
　　Influenza is an acute respiratory infectious disease caused by the influenza virus that can cause widespread epidemics. It is highly contagious and can cause complications such as pneumonia, bronchitis, and myocarditis. It can aggravate underlying conditions in high-risk groups such as the elderly and the frail, increasing the disease burden and endangering human health. Flu vaccination is the most economical and effective measure to prevent influenza illness and influenza outbreaks. The trivalent influenza vaccine developed by Zhifei Longcoma is suitable for people aged three years and older to prevent infectious diseases caused by the influenza virus and is currently one of the leading influenza prevention products in China and abroad.
　　Zhifei Bio said that the company's independently developed influenza virus split vaccine successfully obtained the "Drug Registration Certificate", which is an important achievement of the company's adherence to the "technology & market" dual-wheel drive, demonstrating the company's innovative R&D capabilities and laying a solid foundation for the company to further expand the market.
　　The trivalent influenza vaccine that has obtained the drug registration certificate this time, together with the company's approved quadrivalent influenza virus split vaccine, the quadrivalent/trivalent influenza virus split vaccine (children's type) that is under review for marketing, the quadrivalent influenza virus split vaccine (ZFA02 adjuvant) in Phase I/II clinical trials, and the trivalent influenza virus split vaccine (ZFA02 adjuvant) that has been approved for clinical trials, constitute a rich variety of influenza vaccine products covering all age groups.
　　In the future, the company will use more high-quality products to serve the public's health needs, strengthen the company's overall competitiveness, and promote the company's sustained and stable development.
https://finance.eastmoney.com/a/202509293526587957.html